Role of magnetic resonance imaging in bladder cancer: Current status and emerging techniques

BJU International

Volumn 110, Issue 10, 2012, Pages 1463-1470

  Green, David A ^a   Durand, Matthieu ^a   Gumpeni, Naveen ^a   Rink, Michael ^a,b   Cha, Eugene K ^a   Karakiewicz, Pierre I ^c   Scherr, Douglas S ^a   Shariat, Shahrokh F ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

bladder cancer; diagnosis; magnetic resonance imaging; prognosis; staging; urothelial carcinoma

Indexed keywords

CISPLATIN; GADOLINIUM; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ACCURACY; BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER INVASION; CANCER STAGING; CONTRAST ENHANCEMENT; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; HUMAN; LYMPH NODE METASTASIS; LYMPHOGRAPHY; MAGNETIC RESONANCE LYMPHOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSURETHRAL RESECTION; TUMOR DIFFERENTIATION;

CONTRAST MEDIA; DEXTRANS; DIFFUSION MAGNETIC RESONANCE IMAGING; HUMANS; LYMPH NODES; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEOPLASM STAGING; URINARY BLADDER NEOPLASMS;

EID: 84868194479     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11129.x     Document Type: Review

References (48)

1. Jemal A, Siegel R, Xu J, Ward E,. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300
2. Ro JY, Staerkel GA, Ayala AG,. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19: 435-53
3. van Rhijn BW, Burger M, Lotan Y, et al,. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 2009; 56: 430-42
4. Stein JP, Lieskovsky G, Cote R, et al,. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001; 19: 666-75 (Pubitemid 32120143)
5. Madersbacher S, Hochreiter W, Burkhard F, et al,. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003; 21: 690-6 (Pubitemid 46621904)
6. Shariat SF, Karakiewicz PI, Palapattu GS, et al,. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 2006; 176: 2414-22; discussion 22 (Pubitemid 44755069)
7. Sonpavde G, Shariat SF,. Preoperative chemotherapy for bladder cancer: a standard waits to be optimally deployed. Cancer 2012; 118: 72-81
8. Collaboration ABCAM-a. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 2005; 48: 202-5; discussion 5-6
9. Shariat SF, Palapattu GS, Karakiewicz PI, et al,. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 2007; 51: 137-49; discussion 49-51
10. Svatek RS, Shariat SF, Novara G, et al,. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 2011; 107: 898-904
11. Zhang J, Gerst S, Lefkowitz RA, Bach A,. Imaging of bladder cancer. Radiol Clin North Am 2007; 45: 183-205 (Pubitemid 44854043)
12. Wong-You-Cheong JJ, Woodward PJ, Manning MA, Sesterhenn IA,. From the Archives of the AFIP: neoplasms of the urinary bladder: radiologic-pathologic correlation. Radiographics 2006; 26: 553-80 (Pubitemid 43515325)
13. Padhani AR, Liu G, Koh DM, et al,. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009; 11: 102-25
14. Koh DM, Collins DJ,. Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol 2007; 188: 1622-35 (Pubitemid 46866868)
15. Hamstra DA, Rehemtulla A, Ross BD,. Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. J Clin Oncol 2007; 25: 4104-9 (Pubitemid 47495868)
16. Kobayashi S, Koga F, Yoshida S, et al,. Diagnostic performance of diffusion-weighted magnetic resonance imaging in bladder cancer: potential utility of apparent diffusion coefficient values as a biomarker to predict clinical aggressiveness. Eur Radiol 2011; 21: 2178-86
17. Lahaye MJ, Beets GL, Engelen SM, et al,. Locally advanced rectal cancer: MR imaging for restaging after neoadjuvant radiation therapy with concomitant chemotherapy. Part II. What are the criteria to predict involved lymph nodes? Radiology 2009; 252: 81-91
18. Bellin MF, Roy C,. Magnetic resonance lymphography. Curr Opin Urol 2007; 17: 65-9 (Pubitemid 44901092)
19. Hall MC, Chang SS, Dalbagni G, et al,. Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 2007; 178: 2314-30 (Pubitemid 350080987)
20. Jones JS, Larchian WA,. Non-muscle-invasive bladder cancer (Ta, T1, and CIS. In, Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA, eds, Campbell-Walsh Urology, Vol. 10. Chapter 81-Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Philadelphia, PA: Elsevier, 2011: 2335-54
21. Cowan NC, Crew JP,. Imaging bladder cancer. Curr Opin Urol 2010; 20: 409-13
22. Kim B, Semelka RC, Ascher SM, Chalpin DB, Carroll PR, Hricak H,. Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology 1994; 193: 239-45
23. Totaro A, Pinto F, Brescia A, et al,. Imaging in bladder cancer: present role and future perspectives. Urol Int 2010; 85: 373-80
24. Tekes A, Kamel IR, Imam K, Chan TY, Schoenberg MP, Bluemke DA,. MR imaging features of transitional cell carcinoma of the urinary bladder. AJR Am J Roentgenol 2003; 180: 771-7 (Pubitemid 36237227)
25. Tekes A, Kamel I, Imam K, et al,. Dynamic MRI of bladder cancer: evaluation of staging accuracy. AJR Am J Roentgenol 2005; 184: 121-7 (Pubitemid 40040915)
26. Barentsz JO, Jager GJ, van Vierzen PB, et al,. Staging urinary bladder cancer after transurethral biopsy: value of fast dynamic contrast-enhanced MR imaging. Radiology 1996; 201: 185-93 (Pubitemid 26314386)
27. Hayashi N, Tochigi H, Shiraishi T, Takeda K, Kawamura J,. A new staging criterion for bladder carcinoma using gadolinium-enhanced magnetic resonance imaging with an endorectal surface coil: a comparison with ultrasonography. BJU Int 2000; 85: 32-6 (Pubitemid 30072445)
28. Takeuchi M, Sasaki S, Ito M, et al,. Urinary bladder cancer: diffusion-weighted MR imaging-accuracy for diagnosing T stage and estimating histologic grade. Radiology 2009; 251: 112-21
29. El-Assmy A, Abou-El-Ghar ME, Mosbah A, et al,. Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol 2009; 19: 1575-81
30. Giannarini G, Petralia G, Thoeny HC,. Potential and limitations of diffusion-weighted magnetic resonance imaging in kidney, prostate, and bladder cancer including pelvic lymph node staging: a critical analysis of the literature. Eur Urol 2012; 61: 326-40
31. Canter D, Long C, Kutikov A, et al,. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int 2011; 107: 58-62
32. Grossman HB, Natale RB, Tangen CM, et al,. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003; 349: 859-66 (Pubitemid 37025405)
33. Kim JK, Park SY, Ahn HJ, Kim CS, Cho KS,. Bladder cancer: analysis of multi-detector row helical CT enhancement pattern and accuracy in tumor detection and perivesical staging. Radiology 2004; 231: 725-31 (Pubitemid 38668089)
34. Stenzl A, Cowan NC, De Santis M, et al,. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines. Eur Urol 2011; 59: 1009-18
35. von der Maase H, Sengelov L, Roberts JT, et al,. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8 (Pubitemid 46224062)
36. Barentsz JO, Engelbrecht MR, Witjes JA, de la Rosette JJ, van der Graaf M,. MR imaging of the male pelvis. Eur Radiol 1999; 9: 1722-36
37. Deserno WM, Harisinghani MG, Taupitz M, et al,. Urinary bladder cancer: preoperative nodal staging with ferumoxtran-10-enhanced MR imaging. Radiology 2004; 233: 449-56 (Pubitemid 39423804)
38. Saokar A, Islam T, Jantsch M, Saksena MA, Hahn PF, Harisinghani MG,. Detection of lymph nodes in pelvic malignancies with Computed Tomography and Magnetic Resonance Imaging. Clin Imaging 2010; 34: 361-6
39. Jensen TK, Holt P, Gerke O, et al,. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology. Scand J Urol Nephrol 2011; 45: 122-8
40. Papalia R, Simone G, Grasso R, et al,. Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases. BJU Int 2012; 109: 1031-6
41. Briganti A,. How to improve the ability to detect pelvic lymph node metastases of urologic malignancies. Eur Urol 2009; 55: 770-2
42. Thoeny HC, Triantafyllou M, Birkhaeuser FD, et al,. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging reliably detect pelvic lymph node metastases in normal-sized nodes of bladder and prostate cancer patients. Eur Urol 2009; 55: 761-9
43. Dobson MJ, Carrington BM, Collins CD, et al,. The assessment of irradiated bladder carcinoma using dynamic contrast-enhanced MR imaging. Clin Radiol 2001; 56: 94-8
44. Schrier BP, Peters M, Barentsz JO, Witjes JA,. Evaluation of chemotherapy with magnetic resonance imaging in patients with regionally metastatic or unresectable bladder cancer. Eur Urol 2006; 49: 698-703 (Pubitemid 43374733)
45. Yoshida S, Koga F, Kawakami S, et al,. Initial experience of diffusion-weighted magnetic resonance imaging to assess therapeutic response to induction chemoradiotherapy against muscle-invasive bladder cancer. Urology 2010; 75: 387-91
46. Shipley WU, Kaufman DS, Zehr E, et al,. Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-7; discussion 7-8 (Pubitemid 34722947)
47. Chung PW, Bristow RG, Milosevic MF, et al,. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007; 25: 303-9 (Pubitemid 47031001)
48. Barentsz JO, Jager GJ, Witjes JA, Ruijs JH,. Primary staging of urinary bladder carcinoma: the role of MRI and a comparison with CT. Eur Radiol 1996; 6: 129-33 (Pubitemid 126462772)